| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... The Lancet 394 (10215), 2184-2196, 2019 | 1087 | 2019 |
| A survey of liver transplantation from living adult donors in the United States RS Brown Jr, MW Russo, M Lai, ML Shiffman, MC Richardson, ... New England Journal of Medicine 348 (9), 818-825, 2003 | 598 | 2003 |
| The clinical significance of persistently normal ALT in chronic hepatitis B infection M Lai, BJ Hyatt, I Nasser, M Curry, NH Afdhal Journal of hepatology 47 (6), 760-767, 2007 | 460 | 2007 |
| GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease R Loomba, Z Kayali, M Noureddin, P Ruane, EJ Lawitz, M Bennett, ... Gastroenterology 155 (5), 1463-1473. e6, 2018 | 308 | 2018 |
| The BCKDH kinase and phosphatase integrate BCAA and lipid metabolism via regulation of ATP-citrate lyase PJ White, RW McGarrah, PA Grimsrud, SC Tso, WH Yang, JM Haldeman, ... Cell metabolism 27 (6), 1281-1293. e7, 2018 | 267 | 2018 |
| Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension N Chalasani, MF Abdelmalek, G Garcia-Tsao, R Vuppalanchi, N Alkhouri, ... Gastroenterology 158 (5), 1334-1345. e5, 2020 | 257 | 2020 |
| Saroglitazar, a PPAR‐α/γ agonist, for treatment of NAFLD: a randomized controlled double‐blind phase 2 trial S Gawrieh, M Noureddin, N Loo, R Mohseni, V Awasty, K Cusi, ... Hepatology 74 (4), 1809-1824, 2021 | 239 | 2021 |
| Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis P An, LL Wei, S Zhao, DY Sverdlov, KA Vaid, M Miyamoto, K Kuramitsu, ... Nature communications 11 (1), 2362, 2020 | 222 | 2020 |
| Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis M Kornek, M Lynch, SH Mehta, M Lai, M Exley, NH Afdhal, D Schuppan Gastroenterology 143 (2), 448-458, 2012 | 212 | 2012 |
| ChREBP regulates fructose-induced glucose production independently of insulin signaling MS Kim, SA Krawczyk, L Doridot, AJ Fowler, JX Wang, SA Trauger, ... The Journal of clinical investigation 126 (11), 4372-4386, 2019 | 207 | 2019 |
| Standard assessments of frailty are validated predictors of mortality in hospitalized patients with cirrhosis EB Tapper, D Finkelstein, MA Mittleman, G Piatkowski, M Lai Hepatology 62 (2), 584-590, 2015 | 198 | 2015 |
| Fibrosis assessment in nonalcoholic fatty liver disease (NAFLD) in 2016 DH Kaswala, M Lai, NH Afdhal Digestive diseases and sciences 61, 1356-1364, 2016 | 185 | 2016 |
| The performance of vibration controlled transient elastography in a US cohort of patients with nonalcoholic fatty liver disease EB Tapper, T Challies, I Nasser, NH Afdhal, M Lai Official journal of the American College of Gastroenterology| ACG 111 (5 …, 2016 | 174 | 2016 |
| A quality improvement initiative reduces 30-day rate of readmission for patients with cirrhosis EB Tapper, D Finkelstein, MA Mittleman, G Piatkowski, M Chang, M Lai Clinical Gastroenterology and Hepatology 14 (5), 753-759, 2016 | 161 | 2016 |
| Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension G Garcia-Tsao, J Bosch, Z Kayali, SA Harrison, MF Abdelmalek, E Lawitz, ... Journal of hepatology 72 (5), 885-895, 2020 | 141 | 2020 |
| Liver fibrosis determination. M Lai, NH Afdhal Gastroenterology Clinics of North America 48 (2), 281-289, 2019 | 109 | 2019 |
| Cost-effective evaluation of nonalcoholic fatty liver disease with NAFLD fibrosis score and vibration controlled transient elastography EB Tapper, N Sengupta, MMG Hunink, NH Afdhal, M Lai Official journal of the American College of Gastroenterology| ACG 110 (9 …, 2015 | 86 | 2015 |
| Weight loss results in significant improvements in quality of life for patients with nonalcoholic fatty liver disease: a prospective cohort study EB Tapper, M Lai Hepatology 63 (4), 1184-1189, 2016 | 69 | 2016 |
| Cost-effectiveness analysis: risk stratification of nonalcoholic fatty liver disease (NAFLD) by the primary care physician using the NAFLD fibrosis score EB Tapper, MGM Hunink, NH Afdhal, M Lai, N Sengupta PLoS One 11 (2), e0147237, 2016 | 69 | 2016 |
| Simple non-invasive biomarkers of advanced fibrosis in the evaluation of non-alcoholic fatty liver disease EB Tapper, K Krajewski, M Lai, T Challies, R Kane, N Afdhal, D Lau Gastroenterology report 2 (4), 276-280, 2014 | 69 | 2014 |
